帕吉昔单抗 （INN ：Pagibaximab）是一种嵌合单克隆抗体 ，用于预防低出生体重婴儿 的葡萄球菌 败血症 。截至2010年3月，该药物尚在进行II/III期临床试验 。[1] [2]
参考资料 [ 编辑 ]
^ Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates . Antimicrobial Agents and Chemotherapy. July 2009, 53 (7): 2879–86. PMC 2704668 PMID 19380597 doi:10.1128/AAC.01565-08 ^ Clinical trial number NCT00646399
. PMID 19380597. doi:10.1128/AAC.01565-08.
